{"id":"parcopa","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL1201236","moleculeType":"Small molecule","molecularWeight":"226.23"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"e1ff4c1f-5d6f-44a6-a0f6-d7ca2a94adb9","title":"PARCOPA (CARBIDOPA AND LEVODOPA) TABLET, ORALLY DISINTEGRATING [SCHWARZ PHARMA]"},"ecosystem":[],"_scrapedAt":"2026-03-27T23:59:46.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05781711","phase":"PHASE2","title":"Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-01-06","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT06113640","phase":"PHASE2, PHASE3","title":"Montelukast in Parkinson Disease","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2023-11-05","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT07151378","phase":"PHASE3","title":"Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-10-27","conditions":"PARKINSON DISEASE (Disorder)","enrollment":150},{"nctId":"NCT04469959","phase":"PHASE2","title":"Dopaminergic Dysfunction in Late-Life Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-15","conditions":"Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant","enrollment":100},{"nctId":"NCT06831500","phase":"PHASE1, PHASE2","title":"Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.","status":"RECRUITING","sponsor":"Julien Bally","startDate":"2025-07-18","conditions":"Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic, Parkinson Disease","enrollment":36},{"nctId":"NCT06075771","phase":"PHASE4","title":"Dopaminergic Therapy for Anhedonia - 2","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-11-21","conditions":"Anhedonia, Depression","enrollment":70},{"nctId":"NCT05043103","phase":"","title":"Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2021-07-06","conditions":"Advanced Parkinson Disease","enrollment":312},{"nctId":"NCT06785298","phase":"PHASE2, PHASE3","title":"Fexofenadine as Adjuvant Therapy in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT06587217","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-10-29","conditions":"Parkinsonian Signs in Older Persons","enrollment":5},{"nctId":"NCT07229664","phase":"PHASE2, PHASE3","title":"Vinpocetine in Patients With Parkinsonian Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-10","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT05708274","phase":"PHASE1","title":"Pharmacological Agents for Chronic Spinal Cord Injury (SCI)","status":"COMPLETED","sponsor":"Bronx VA Medical Center","startDate":"2023-01-20","conditions":"Spinal Cord Injuries","enrollment":25},{"nctId":"NCT07246278","phase":"PHASE1, PHASE2","title":"Celecoxib in Parkinson Disease as Adjuvant Therapy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-20","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT07229651","phase":"PHASE2, PHASE3","title":"Metformin in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-10","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT03022318","phase":"PHASE2","title":"Carbidopa-levodopa in Neovascular AMD","status":"COMPLETED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2017-05-02","conditions":"Age-related Macular Degeneration","enrollment":20},{"nctId":"NCT03023059","phase":"PHASE2","title":"Dose Ranging Study of Carbidopa-levodopa","status":"COMPLETED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2017-05-02","conditions":"Age-related Macular Degeneration","enrollment":35},{"nctId":"NCT03197493","phase":"PHASE2","title":"Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2017-08-01","conditions":"Macula; Degeneration, Retina","enrollment":35},{"nctId":"NCT07001150","phase":"PHASE2","title":"Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-05-10","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT04750226","phase":"PHASE3","title":"Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-02-18","conditions":"Parkinson's Disease (PD)","enrollment":118},{"nctId":"NCT05962957","phase":"PHASE2","title":"Role of Pentoxifylline and Celecoxib in Parkinsonism","status":"COMPLETED","sponsor":"Mostafa Bahaa","startDate":"2023-08-07","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT04379050","phase":"PHASE3","title":"Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-06-08","conditions":"Parkinson's Disease (PD)","enrollment":130},{"nctId":"NCT04821830","phase":"PHASE4","title":"Vigor and the LDR in Parkinson Disease","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2020-02-12","conditions":"Parkinson Disease","enrollment":19},{"nctId":"NCT05471609","phase":"EARLY_PHASE1","title":"Sustained Release Oral Formulation for Treatment of Parkinson's Disease","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-06-12","conditions":"Healthy Volunteers","enrollment":6},{"nctId":"NCT06219915","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-03-15","conditions":"Parkinsonian Signs in Older Persons","enrollment":13},{"nctId":"NCT02994719","phase":"","title":"Gait Analysis in Neurological Disease","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-03-01","conditions":"Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease","enrollment":120},{"nctId":"NCT02726386","phase":"PHASE2","title":"A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2016-05-04","conditions":"Parkinson's Disease","enrollment":214},{"nctId":"NCT04006210","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2019-09-30","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT06976346","phase":"PHASE1","title":"Relative Bioavailability Study of HRG2010 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-09-10","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT05132660","phase":"EARLY_PHASE1","title":"Treating Early Stage Diabetic Retinopathy","status":"ENROLLING_BY_INVITATION","sponsor":"VA Office of Research and Development","startDate":"2022-07-01","conditions":"Diabetic Retinopathy","enrollment":244},{"nctId":"NCT06596876","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-11-06","conditions":"Parkinson's Disease","enrollment":450},{"nctId":"NCT05369533","phase":"PHASE1, PHASE2","title":"Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-08-01","conditions":"Stroke","enrollment":25},{"nctId":"NCT05885360","phase":"PHASE4","title":"Istradefylline Effect Protocol on Parkinson's Disease Tremor","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2023-01-20","conditions":"Parkinson Disease, Tremor","enrollment":27},{"nctId":"NCT06432309","phase":"NA","title":"Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital of Ferrara","startDate":"2022-07-01","conditions":"Parkinson Disease, Effect of Drug","enrollment":22},{"nctId":"NCT04735627","phase":"NA","title":"Real-Time Levodopa Level Monitoring in Parkinson Disease","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2021-12-07","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT06003608","phase":"","title":"Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nimble Science Ltd.","startDate":"2024-02-19","conditions":"Parkinson Disease","enrollment":100},{"nctId":"NCT05285683","phase":"PHASE2","title":"The Role of Brain Dopamine in Chronic Pain","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2024-01-31","conditions":"Chronic Pain","enrollment":10},{"nctId":"NCT04723147","phase":"PHASE4","title":"DTA (Dopaminergic Therapy for Anhedonia) Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-01-29","conditions":"Depression, Anhedonia","enrollment":19},{"nctId":"NCT05463367","phase":"PHASE2","title":"Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2021-01-01","conditions":"Opioid Use, Opioid Dependence, Opioid-use Disorder","enrollment":60},{"nctId":"NCT03735901","phase":"PHASE3","title":"Enhancement of Stroke Rehabilitation With Levodopa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-06-14","conditions":"Acute Stroke, Stroke Rehabilitation","enrollment":610},{"nctId":"NCT06626152","phase":"PHASE2","title":"Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2024-08-15","conditions":"Major Depressive Disorder","enrollment":50},{"nctId":"NCT06614153","phase":"PHASE2","title":"Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-05-16","conditions":"Parkinson's Disease","enrollment":61},{"nctId":"NCT01725802","phase":"PHASE1","title":"A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2012-12-16","conditions":"Parkinson's Disease","enrollment":8},{"nctId":"NCT02096601","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-08-11","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT00456794","phase":"PHASE2","title":"12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-03","conditions":"Parkinson's Disease","enrollment":325},{"nctId":"NCT00199420","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-07","conditions":"Parkinson's Disease","enrollment":580},{"nctId":"NCT00955045","phase":"PHASE2, PHASE3","title":"A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-08","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT00456586","phase":"PHASE2","title":"12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-04","conditions":"Parkinson's Disease","enrollment":180},{"nctId":"NCT03451500","phase":"PHASE2","title":"Carbidopa-Levodopa in Dry AMD With Geographic Atrophy","status":"TERMINATED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2018-07-01","conditions":"Age Related Macular Degeneration","enrollment":7},{"nctId":"NCT00199407","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-06","conditions":"Parkinson's Disease","enrollment":230},{"nctId":"NCT02763137","phase":"PHASE2","title":"Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients","status":"COMPLETED","sponsor":"IRCCS San Raffaele Roma","startDate":"2014-07-30","conditions":"Parkinson Disease","enrollment":18},{"nctId":"NCT04325503","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-02-08","conditions":"Parkinsonian Signs in Older Persons","enrollment":14},{"nctId":"NCT05087914","phase":"PHASE2","title":"Novel Non-opioid Post-surgical Pain Treatment in Females","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2021-11-01","conditions":"Acute Pain, Bunionectomy, Toe Fusion","enrollment":""},{"nctId":"NCT03111485","phase":"PHASE4","title":"Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2017-05-24","conditions":"Parkinson's Disease, Obstructive Sleep Apnea","enrollment":36},{"nctId":"NCT02480803","phase":"PHASE4","title":"INfusion VErsus STimulation in Parkinson's Disease","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-12-19","conditions":"Parkinson's Disease","enrollment":51},{"nctId":"NCT06236230","phase":"PHASE4","title":"Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-11-15","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT02604914","phase":"PHASE1","title":"A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-05-29","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT01486628","phase":"PHASE1","title":"Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2012-04-30","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT01883505","phase":"PHASE2","title":"A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-01-06","conditions":"Parkinson's Disease","enrollment":30},{"nctId":"NCT00439049","phase":"","title":"Substance Abuse Pre-Treatment Screening Study","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2005-10","conditions":"Cocaine Abuse, Cocaine Dependence, Opiate Dependence","enrollment":7500},{"nctId":"NCT03000569","phase":"PHASE2","title":"A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-11-30","conditions":"Parkinson Disease","enrollment":29},{"nctId":"NCT06115538","phase":"PHASE4","title":"Comparison of Dopamin Level in Idiopathic Parkinson's Patients","status":"UNKNOWN","sponsor":"Ankara Ataturk Sanatorium Training and Research Hospital","startDate":"2023-10-01","conditions":"Parkinson Disease, Treatment Adherence","enrollment":96},{"nctId":"NCT02549092","phase":"PHASE3","title":"A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-26","conditions":"Advanced Parkinson's Disease","enrollment":89},{"nctId":"NCT03781167","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-04-29","conditions":"Parkinson's Disease (PD)","enrollment":244},{"nctId":"NCT04052776","phase":"PHASE1","title":"Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2020-09-11","conditions":"Spinal Cord Injuries, Drug Effect","enrollment":3},{"nctId":"NCT02549573","phase":"PHASE4","title":"Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®","status":"TERMINATED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2016-01","conditions":"Parkinson's Disease, Motor Symptoms","enrollment":13},{"nctId":"NCT01770145","phase":"PHASE4","title":"Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)","status":"COMPLETED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2012-12","conditions":"Parkinson's Disease, Motor Symptoms, Akinesia","enrollment":127},{"nctId":"NCT03944785","phase":"","title":"Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2017-11-30","conditions":"Idiopathic Parkinson Disease","enrollment":164},{"nctId":"NCT02577523","phase":"PHASE2","title":"A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-12-29","conditions":"Parkinson's Disease","enrollment":38},{"nctId":"NCT03761030","phase":"PHASE4","title":"L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-01-09","conditions":"Major Depressive Disorder, Dysthymia, Depression","enrollment":51},{"nctId":"NCT04493320","phase":"PHASE4","title":"1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-02-10","conditions":"Depression, Cognitive Impairment, Gait Impairment","enrollment":5},{"nctId":"NCT00590122","phase":"PHASE4","title":"Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT04952194","phase":"PHASE4","title":"Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-01","conditions":"Parkinson Disease","enrollment":180},{"nctId":"NCT04742348","phase":"PHASE4","title":"Research on Translational Outcomes of Alcohol (Project RETRO)","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2023-02","conditions":"Alcohol Drinking","enrollment":""},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT05083260","phase":"PHASE1, PHASE2","title":"NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa","status":"COMPLETED","sponsor":"BioVie Inc.","startDate":"2022-01-04","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT04650217","phase":"PHASE4","title":"Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-10-07","conditions":"Depressive Disorder","enrollment":1},{"nctId":"NCT04500106","phase":"","title":"Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-04-22","conditions":"Parkinson's Disease","enrollment":41},{"nctId":"NCT00660673","phase":"PHASE3","title":"Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2009-11-13","conditions":"Advanced Parkinson's Disease","enrollment":262},{"nctId":"NCT04787965","phase":"","title":"Opicapone Treatment Initiation Open-Label Study","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2021-03-01","conditions":"Parkinson Disease","enrollment":239},{"nctId":"NCT04380142","phase":"PHASE3","title":"Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-10-19","conditions":"Parkinson's Disease (PD)","enrollment":174},{"nctId":"NCT04000919","phase":"PHASE2, PHASE3","title":"Effects of 5HTP and LDOPA on CNS Excitability After SCI","status":"SUSPENDED","sponsor":"Jessica M D'Amico","startDate":"2019-06-19","conditions":"Spinal Cord Injuries","enrollment":30},{"nctId":"NCT03205956","phase":"PHASE1","title":"Measuring Parkinson's Disease Progression","status":"COMPLETED","sponsor":"Kevin J. Black, MD","startDate":"2017-10-19","conditions":"Parkinson's Disease","enrollment":31},{"nctId":"NCT02513485","phase":"PHASE4","title":"Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-10-09","conditions":"Depression","enrollment":57},{"nctId":"NCT04778176","phase":"PHASE2","title":"Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"SynAgile Corporation","startDate":"2021-06-16","conditions":"Parkinson's Disease","enrollment":17},{"nctId":"NCT03929068","phase":"PHASE1","title":"Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-05-13","conditions":"Amyotrophic Lateral Sclerosis, Motor Neuron Disease","enrollment":15},{"nctId":"NCT03007888","phase":"PHASE2","title":"A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2016-11-14","conditions":"Advanced Parkinson's Disease","enrollment":28},{"nctId":"NCT05250141","phase":"PHASE1","title":"Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2022-02-14","conditions":"Bioequivalence","enrollment":44},{"nctId":"NCT02346630","phase":"PHASE4","title":"Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation","status":"WITHDRAWN","sponsor":"Ross D. Zafonte, MD","startDate":"2015-03","conditions":"Stroke","enrollment":""},{"nctId":"NCT02611713","phase":"","title":"Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-04","conditions":"Advanced Parkinson's Disease","enrollment":213},{"nctId":"NCT05128175","phase":"PHASE1","title":"Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions","status":"UNKNOWN","sponsor":"Shanghai WD Pharmaceutical Co., Ltd.","startDate":"2021-10-29","conditions":"Parkinson Disease","enrollment":15},{"nctId":"NCT05036473","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease","status":"UNKNOWN","sponsor":"Shanghai WD Pharmaceutical Co., Ltd.","startDate":"2021-10-12","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT04441697","phase":"","title":"Sleepiness in Parkinson's Patients With Continuous Dopaminergic Delivery Device or Deep Brain Stimulation","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2020-06-01","conditions":"Parkinson Disease","enrollment":30},{"nctId":"NCT01736176","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2013-03","conditions":"Advanced Parkinson's Disease","enrollment":39},{"nctId":"NCT02485600","phase":"","title":"Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-19","conditions":"Parkinson Disease (PD)","enrollment":88},{"nctId":"NCT03055936","phase":"PHASE1","title":"Dose-finding Pharmacokinetic Study in Healthy Males","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2017-02-21","conditions":"Healthy Volunteers","enrollment":56},{"nctId":"NCT02082249","phase":"PHASE3","title":"An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-03-10","conditions":"Advanced Parkinson's Disease","enrollment":30},{"nctId":"NCT00914602","phase":"PHASE1, PHASE2","title":"An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2009-05","conditions":"Parkinson's Disease","enrollment":14},{"nctId":"NCT01951105","phase":"PHASE4","title":"Effect of L-dopa In Subacute Back Pain Population","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-02-24","conditions":"Sub-acute Back Pain","enrollment":72},{"nctId":"NCT01683253","phase":"PHASE4","title":"Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-11","conditions":"Impulse Control Disorder","enrollment":150},{"nctId":"NCT01171313","phase":"PHASE2","title":"A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2010-07","conditions":"Parkinson's Disease","enrollment":35},{"nctId":"NCT02381444","phase":"","title":"Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-17","conditions":"Parkinson's Disease (PD)","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Parcopa","genericName":"Parcopa","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}